49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances

Algorithmic Diagnostic Approach to Hyponatremia

Hyponatremia, defined as a serum sodium concentration < 135 mEq/L, is the most common electrolyte disturbance in clinical practice. The clinical evaluation must follow a disciplined, stepwise diagnostic algorithm based on serum osmolality and clinical extracellular volume status.

Step 1: Determine Serum Osmolality

Normal serum osmolality ranges from 275 to 295 mOsm/kg. Hyponatremia is categorized into three distinct pathophysiologic states:

1. Hypertonic Hyponatremia (Serum Osmolality > 295 mOsm/kg):
   • Caused by the presence of unmeasured, impermeant osmoles in the intravascular space that draw water out of cells into the extracellular fluid, diluting measured sodium. Prototypic cause: severe hyperglycemia (or IV mannitol/glycerol administration).
   • Corrected Sodium Formula: $\text{Corrected } [\text{Na}^+] = \text{Measured } [\text{Na}^+] + 1.6 \times \left(\frac{\text{Glucose} - 100}{100}\right)$
2. Isotonic Hyponatremia (Serum Osmolality 275 to 295 mOsm/kg) — Pseudohyponatremia:
   • An in vitro laboratory artifact occurring when conventional indirect ion-selective electrodes (ISE) are used. In states of severe hypertriglyceridemia (triglycerides > 1,000 to 1,500 mg/dL) or profound hyperproteinemia / paraproteinemia (multiple myeloma, Waldenström macroglobulinemia), the non-aqueous (lipid/protein) phase of plasma expands from its normal 7% to >20%. The measured sodium per total volume appears artificially low, even though true aqueous sodium concentration and plasma osmolality are normal. Confirmed by measuring sodium via direct ISE (blood gas analyzer).
3. Hypotonic Hyponatremia (Serum Osmolality < 275 mOsm/kg):
   • Represents true physiological hypotonicity and excess of free water relative to sodium. Proceed immediately to Step 2.

Step 2: Determine Extracellular Fluid (ECF) Volume Status

In hypotonic hyponatremia, the patient's clinical volume status and urinary electrolytes narrow the differential diagnosis:

               DIFFERENTIAL OF HYPOTONIC HYPONATREMIA (< 275 mOsm/kg)

   Volume Status    Clinical Signs        Urine Osm / Urine Na        Etiologies & First-Line Therapy
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   Hypovolemic      Dry mucosa, poor      • Extrarenal Losses:        Extrarenal: Vomiting, diarrhea,
                    turgor, orthostasis,    Urine Na < 20 mEq/L       sweating, burns, pancreatitis.
                    tachycardia, flat JVP • Renal Losses:             Renal: Diuretics, hypoaldosterone,
                                            Urine Na > 20 mEq/L       cerebral salt wasting.
                                          Urine Osm > 300 mOsm/kg     Rx: 0.9% Normal Saline bolus.

   Hypervolemic     Peripheral edema,     • Urine Na < 20 mEq/L       Congestive heart failure, liver
                    ascites, elevated       (avidity from low ECV)    cirrhosis, nephrotic syndrome.
                    JVP, bibasilar rales  • Urine Na > 20 mEq/L       Acute or chronic kidney injury.
                                            (in renal failure)        Rx: Fluid/Na restriction + Loops.

   Euvolemic        Normal skin turgor,   • SIADH:                    SIADH (malignancy, CNS, drugs),
                    moist mucosa, no        Urine Osm > 100 mOsm/kg   severe hypothyroidism, secondary
                    edema, normal JVP       Urine Na > 20-40 mEq/L    adrenal insufficiency.
                                          • Psychogenic Polydipsia:   Rx: Fluid restriction (<800 mL/d),
                                            Urine Osm < 100 mOsm/kg   oral salt tabs, urea, vaptans.
   ═════════════════════════════════════════════════════════════════════════════════════════════════

Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

SIADH is the most common cause of euvolemic hypotonic hyponatremia. Persistent, non-physiologic ADH (arginine vasopressin) release causes water reabsorption in the collecting ducts via V2 receptors and aquaporin-2 channels.

• Diagnostic Criteria: Hypotonic hyponatremia (serum Osm <275 mOsm/kg), inappropriately concentrated urine (urine Osm > 100 mOsm/kg, often >300 mOsm/kg), natriuresis (urine Na > 20 to 40 mEq/L reflecting euvolemic sodium excretion), and normal adrenal, thyroid, and renal function in the absence of diuretic therapy.
• Etiologies: Central nervous system disorders (stroke, subdural hematoma, trauma, infection), pulmonary disease (small cell lung cancer [ectopic ADH], pneumonia, tuberculosis), and medications (SSRIs/SNRIs, carbamazepine, oxcarbazepine, cyclophosphamide, NSAIDs).
• Management: Fluid restriction to < 800 to 1,000 mL/day is the cornerstone. Oral sodium chloride tablets (2-3 g TID) combined with low-dose loop diuretics (furosemide 20 mg daily to disrupt the medullary concentration gradient), oral urea packets (induces osmotic water diuresis), or vasopressin receptor antagonists (tolvaptan) for refractory cases.

Acute Severe Hyponatremia & Correction Limits

• Acute Symptomatic Hyponatremia (<48 hours duration): Presents with severe cerebral edema: seizures, lethargy, respiratory arrest, brainstem herniation.
  • Emergency Protocol: Administer 3% Hypertonic Saline 100 mL IV bolus over 10 minutes. This can be repeated up to two times (maximum 300 mL) at 10-minute intervals if severe neuro symptoms persist, aiming for a rapid 4 to 6 mEq/L rise in serum sodium to halt cerebral herniation.
• Chronic Hyponatremia (>48 hours duration) & The ODS Mandate: In chronic hyponatremia, cerebral astrocytes adapt by extruding intracellular organic osmolytes (taurine, myo-inositol, glutamate) to normalize brain cell volume.

[!CAUTION] THE ABSOLUTE SAFETY RULE: PREVENTING OSMOTIC DEMYELINATION SYNDROME (ODS) In chronic hyponatremia, rapid elevation of extracellular sodium shrinks brain cells and causes catastrophic Osmotic Demyelination Syndrome (ODS) (formerly central pontine myelinolysis).

Patients typically improve initially, but 2 to 6 days later develop irreversible dysarthria, dysphagia, horizontal gaze paralysis, spastic quadriparesis, and locked-in syndrome.

MAXIMUM CORRECTION LIMIT: Serum sodium elevation must NOT EXCEED <= 8 mEq/L in any 24-hour period (and <= 4 to 6 mEq/L in 24 hours in high-risk patients: liver cirrhosis, severe malnutrition, advanced alcoholism, hypokalemia). If accidental overcorrection occurs, immediately discontinue saline and administer IV free water (5% Dextrose) and Desmopressin (dDAVP 1 to 2 mcg IV/SC) to re-lower sodium into safe limits.

---

Hyperkalemia: Mechanisms, ECG Progression & Stabilization

Hyperkalemia (serum potassium > 5.0 to 5.5 mEq/L) is a life-threatening arrhythmogenic emergency. Serum potassium is normally maintained between 3.5 and 5.0 mEq/L, with >98% sequestered intracellularly.

Etiology

• Impaired Renal Excretion: Acute kidney injury, chronic kidney disease (GFR <30 mL/min), hypoaldosteronism (type 4 renal tubular acidosis).
• Pharmacologic Inhibition of the RAAS: ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Mineralocorticoid Receptor Antagonists (spironolactone, eplerenone), direct renin inhibitors, and NSAIDs (blunt renin release).
• Tubular Potassium Blockade: Trimethoprim (inhibits apical epithelial sodium channels [ENaC] in the collecting tubule, mimicking amiloride), calcineurin inhibitors (tacrolimus, cyclosporine).
• Extracellular Potassium Shifts: Severe metabolic acidosis (H+/K+ exchange), insulin deficiency, beta-blocker therapy, cell breakdown (rhabdomyolysis, tumor lysis syndrome, massive hemolysis).

Diagnostic Electrophysiologic Sequence on ECG

As extracellular potassium rises, resting membrane potential depolarizes (becomes less negative), partially inactivating voltage-gated sodium channels and accelerating repolarization:

1. Peaked, Narrow-Based, Symmetric T Waves: The earliest ECG manifestation (K+ ~5.5 to 6.5 mEq/L), most prominent in precordial leads V2-V4.
2. PR Interval Prolongation & P Wave Flattening: Progressive delay in atrioventricular conduction (K+ ~6.5 to 7.5 mEq/L); P waves eventually disappear entirely (sinoventricular rhythm).
3. QRS Complex Widening: Intraventricular conduction delay (K+ ~7.5 to 8.0 mEq/L), merging with the ST segment and T wave.
4. "Sine Wave" Pattern: Extreme, terminal conduction delay where widened QRS complexes blend directly into T waves. Imminent harbinger of ventricular fibrillation or asystole.

                  ECG PROGRESSION IN HYPERKALEMIA

   Serum K+ Level         Classic ECG Finding                  Clinical Danger
   ─────────────────────────────────────────────────────────────────────────────
   5.5 - 6.5 mEq/L        Tall, peaked, symmetric T waves      Early repolarization disturbance
   6.5 - 7.5 mEq/L        Prolonged PR, flattened P waves      AV conduction slowing
   7.5 - 8.0 mEq/L        Marked QRS widening, lost P waves    Severe intraventricular delay
   > 8.0 mEq/L            "Sine wave" pattern ──► VFib         Lethal pre-terminal arrest
   ─────────────────────────────────────────────────────────────────────────────

The Emergency Stabilization Triad

Managing acute severe hyperkalemia (K+ >=6.5 mEq/L or any hyperkalemic ECG change) demands immediate execution of three distinct steps:

                EMERGENCY PHARMACOTHERAPY FOR HYPERKALEMIA

   Action / Step       Drug & Dosage               Onset & Duration     Mechanism of Action
   ═════════════════════════════════════════════════════════════════════════════════════════════
   1. Membrane         Calcium Gluconate 10%       Onset: 1-3 minutes   Does NOT lower K+;
      Stabilization    10 mL (1 g) IV over 2-5 min Duration: 30-60 min  restores cardiac resting
                       (Repeat in 5-10 min if ECG                       membrane potential threshold,
                       changes persist)                                 preventing lethal arrhythmia

   2. Intracellular    Regular Insulin 10 units IV Onset: 15-30 minutes Drives K+ into cells via
      Shifting         PLUS D50W 25 g (50 mL) IV   Duration: 4-6 hours  Na+/K+-ATPase stimulation.
                       (Omit D50W if glucose >250)                      Lowers K+ by ~0.5-1.2 mEq/L.

                       Nebulized Albuterol         Onset: 30 minutes    Stimulates beta-2 receptors,
                       10 to 20 mg in 4 mL saline  Duration: 2-4 hours  shifting K+ intracellularly.

                       Sodium Bicarbonate          Onset: 30-60 minutes Promotes H+/K+ exchange;
                       50 mEq IV over 5 minutes    Duration: 1-2 hours  effective in severe acidosis.

   3. Potassium        Furosemide 40 to 80 mg IV   Onset: 30-60 minutes Induces renal kaliuresis
      Elimination                                                       in functional kidneys.

                       Sodium Zirconium            Onset: 1 hour        Inorganic crystal binding K+
                       Cyclosilicate (Lokelma)                          in GI tract in exchange
                       10 g PO TID                                      for sodium and hydrogen.

                       Patiromer (Veltassa)        Onset: 4-7 hours     Non-absorbed polymer binding
                       8.4 g PO once daily                              K+ in exchange for calcium.

                       Emergent Hemodialysis       Immediate            Definitive elimination for
                                                                        anuric ESRD or refractory K+.
   ═════════════════════════════════════════════════════════════════════════════════════════════

---

Hypokalemia & The Critical Magnesium Link

Hypokalemia (serum potassium < 3.5 mEq/L) is triggered by gastrointestinal losses (vomiting, diarrhea, laxatives), renal losses (loop or thiazide diuretics, hyperaldosteronism, renal tubular acidosis), or intracellular shifts (alkalosis, beta-agonists, insulin therapy).

Clinical Manifestations & ECG Findings

• Neuromuscular: Generalized muscle weakness, muscle cramps, hyporeflexia, ascending flaccid paralysis, constipation, and paralytic ileus.
• Cardiovascular: Flattened or inverted T waves, prominent U waves (positive wave immediately following T wave), ST-segment depression, prolonged QT/QU intervals, and high risk of ventricular ectopy and torsades de pointes.

Why Magnesium Must Be Checked and Repleted First

[!IMPORTANT] THE CARDINAL PHYSIOLOGIC PEARL: REFRACTORY HYPOKALEMIA AND MAGNESIUM Up to 40% to 50% of hypokalemic patients possess concurrent hypomagnesemia. Clinicians must ALWAYS CHECK AND REPLETE MAGNESIUM (target > 2.0 mg/dL) in any patient with hypokalemia.

Intracellular magnesium exerts a crucial physiologic brake on renal potassium excretion:

1. Magnesium normally binds to and inhibits Renal Outer Medullary Potassium (ROMK) channels in the apical membrane of the cortical collecting duct. In hypomagnesemia, this inhibition is removed, permitting unchecked, torrential potassium leakage into the urine.
2. Magnesium is an essential cofactor for Na+/K+-ATPase pumps. Hypomagnesemia impairs pump activity, preventing potassium uptake into cells.

Consequently, hypokalemia is completely refractory to massive oral or IV potassium repletion until serum magnesium is normalized!

Calcium Derangements: Hypercalcemia & Hypocalcemia

Calcium homeostasis is tightly orchestrated by parathyroid hormone (PTH), calcitriol (1,25-dihydroxyvitamin D), and calcitonin acting on bone, kidneys, and intestines.

Albumin Binding & Corrected Calcium

Approximately 40% to 45% of total serum calcium is bound to plasma proteins, primarily albumin. In hypoalbuminemia (cirrhosis, nephrotic syndrome, malnutrition), measured total calcium appears deceptively low while active ionized calcium remains normal.

• Corrected Calcium Formula: $\text{Corrected Total Calcium (mg/dL)} = \text{Measured Total Calcium} + 0.8 \times (4.0 - \text{Serum Albumin [g/dL]})$
• In critically ill or complex patients, measuring ionized calcium directly (normal 1.15 to 1.30 mmol/L) is the definitive gold standard.

Hypercalcemia (Total Calcium > 10.2 mg/dL or Ionized Ca > 1.30 mmol/L)

Over 90% of all hypercalcemia cases are attributable to two major conditions:

1. Primary Hyperparathyroidism: The predominant cause in ambulatory outpatients (>80%). Characterized by autonomous PTH secretion from a solitary parathyroid adenoma (85%) or multiglandular hyperplasia. Laboratory findings: elevated or "inappropriately normal" intact PTH, hypercalcemia, hypophosphatemia, and hypercalciuria.
2. Hypercalcemia of Malignancy: The predominant cause in hospitalized inpatients (>75%). Characterized by rapid onset, severe symptoms, and suppressed intact PTH (<10 pg/mL). Mechanisms include:
   • Humoral Hypercalcemia of Malignancy (80%): Tumor secretion of PTH-related peptide (PTHrP), seen in squamous cell carcinomas (lung, head/neck, esophagus), renal cell carcinoma, and bladder cancer.
   • Osteolytic Metastases (20%): Extensive osteoclastic bone destruction, seen in multiple myeloma and metastatic breast cancer.
   • Calcitriol-Mediated (Ectopic 1-alpha-hydroxylase): Uncontrolled 1,25-(OH)2D production in lymphomas and granulomatous disorders (sarcoidosis, tuberculosis).

               ACUTE MEDICAL MANAGEMENT OF SEVERE HYPERCALCEMIA

   Therapeutic Modality    Dosage & Route              Onset / Mechanism
   ═════════════════════════════════════════════════════════════════════════════════════════
   1. Aggressive Isotonic  0.9% Normal Saline          Onset: Immediate (within hours).
      Hydration            200 to 300 mL/hr            Restores intravascular volume; promotes
                           (Titrated to urine output)   urinary calciuresis via proximal tubule.

   2. Calcitonin           4 units/kg SC or IM         Onset: 2 to 4 hours.
      (Salmon)             every 12 hours              Inhibits osteoclastic bone resorption and
                                                       enhances calciuresis; acts as a rapid
                                                       bridge; limited by tachyphylaxis at 48h.

   3. Intravenous          Zoledronic Acid 4 mg IV     Onset: 2 to 4 days (Nadir: 4 to 7 days).
      Bisphosphonates      over 15 minutes             Potent, sustained osteoclast apoptosis;
                           OR Pamidronate 60-90 mg IV  drug of choice for malignancy hypercalcemia.

   4. Denosumab            120 mg SC weekly x 3 weeks  Onset: 2 to 4 days.
                           then monthly                Monoclonal antibody against RANKL; ideal
                                                       for bisphosphonate-refractory or CKD.
   ═════════════════════════════════════════════════════════════════════════════════════════

Hypocalcemia (Total Calcium < 8.5 mg/dL or Ionized Ca < 1.15 mmol/L)

• Etiologies: Hypoparathyroidism (post-surgical thyroidectomy or parathyroidectomy), severe vitamin D deficiency, acute pancreatitis (fat saponification binding calcium), chronic kidney disease (impaired calcitriol synthesis), and profound hypomagnesemia (suppresses PTH synthesis and induces PTH end-organ resistance).
• Neuromuscular Hyperexcitability & Physical Signs:
  • Chvostek Sign: Tapping the facial nerve anterior to the ear tragus produces involuntary twitching of ipsilateral facial muscles (angle of mouth, nose, eyelid).
  • Trousseau Sign: Inflation of a blood pressure cuff to 20 mmHg above systolic blood pressure for 3 minutes precipitates painful carpal spasm (flexion of wrist and metacarpophalangeal joints with hyperextension of fingers and adduction of thumb — "main d'accoucheur"). Trousseau sign is significantly more sensitive (94%) and specific (99%) than Chvostek sign.
  • Cardiovascular: Prolongation of the QTc interval, predisposing to ventricular arrhythmias and torsades de pointes.
• Treatment: Acute symptomatic hypocalcemia is treated with IV Calcium Gluconate (1 to 2 g in 50 mL D5W infused over 10 to 20 minutes) under continuous cardiac monitoring.